Semaglutide—widely known by brand names Ozempic and Wegovy—is a GLP‑1 receptor agonist used in clinical settings to support weight management, type 2 diabetes blood‑sugar control, and the reduction of major cardiovascular risks such as heart attack and stroke in eligible patients. As one of the most researched GLP‑1 medications, Semaglutide has become a leading option for individuals seeking improved metabolic health.
Semaglutide works by mimicking the natural hormone GLP‑1. This action helps the body:
• Increase insulin secretion after meals
• Reduce glucagon release, supporting healthier glucose levels
• Slow gastric emptying, promoting longer-lasting fullness
• Decrease appetite and food intake, contributing to sustained weight loss
Through these combined mechanisms, Semaglutide supports better glucose regulation, clinically meaningful weight reduction, and overall metabolic improvements.
For research purposes only. Not for human or veterinary use.
Semaglutide—widely known by brand names Ozempic and Wegovy—is a GLP‑1 receptor agonist used in clinical settings to support weight management, type 2 diabetes blood‑sugar control, and the reduction of major cardiovascular risks such as heart attack and stroke in eligible patients. As one of the most researched GLP‑1 medications, Semaglutide has become a leading option for individuals seeking improved metabolic health.
Semaglutide works by mimicking the natural hormone GLP‑1. This action helps the body:
• Increase insulin secretion after meals
• Reduce glucagon release, supporting healthier glucose levels
• Slow gastric emptying, promoting longer-lasting fullness
• Decrease appetite and food intake, contributing to sustained weight loss
Through these combined mechanisms, Semaglutide supports better glucose regulation, clinically meaningful weight reduction, and overall metabolic improvements.
For research purposes only. Not for human or veterinary use.
